Is Pigmentary Maculopathy from Elmiron permanent?

For years, patients with interstitial cystitis relied on pentosan polysulfate sodium (Elmiron) as the only oral medication approved for the condition. But by 2026, the question is no longer whether Elmiron can cause pigmentary maculopathy—it's how we screen for it, who is liable, and what the standard of care should be. We've tracked the clinical data, the FDA actions, and the litigation outcomes to give you a clear picture of where things stand today.

The connection between Elmiron and a unique form of retinal toxicity—now widely termed "pentosan polysulfate sodium maculopathy"—has been established through dozens of peer-reviewed studies. The drug's manufacturer, Janssen Pharmaceuticals, has updated its prescribing information, but many patients were exposed for years without any warning. Our analysis synthesizes the current evidence, screening protocols, and legal recourse available in 2026.

Janssen's Label Changes and the 2020 FDA Safety Communication

In June 2020, the FDA issued a safety communication alerting healthcare professionals to the risk of pigmentary maculopathy associated with chronic Elmiron use. This followed a landmark 2018 study by Dr. Nieraj Jain at Emory Eye Center, which identified the characteristic pattern of retinal changes in long-term users. By 2026, the drug's label includes a bolded warning about retinal toxicity, recommending baseline and periodic ophthalmic exams for all patients.

Despite these updates, critics argue that the warning came too late. Many patients had already accumulated five, ten, or even fifteen years of cumulative exposure before any official acknowledgment. The latency period between drug initiation and detectable retinal damage remains a key concern—some studies suggest it can take three to five years of continuous use before symptoms appear.

"The evidence linking Elmiron to pigmentary maculopathy is now overwhelming. Multiple independent research groups have replicated the findings, and the pattern of damage—a parafoveal ring of hyperautofluorescence with associated atrophy—is distinct from age-related macular degeneration. For reference, see the original Emory study published in Ophthalmology (2018) and the FDA safety communication at fda.gov. Our ongoing coverage is archived at encyclopedias.biz."

Quantifying the Risk: Cumulative Dose and Prevalence Data

The risk is not uniform across all users. Research consistently shows a dose-response relationship: the higher the cumulative exposure, the greater the likelihood of developing maculopathy. We've compiled data from the three largest cohort studies published between 2018 and 2025 to illustrate this trend.

These figures underscore a troubling reality: even at lower cumulative doses, a significant minority of patients develop retinal changes. The condition is often asymptomatic in early stages, making routine screening essential. Patients who have taken Elmiron for more than three years, or who have a cumulative dose exceeding 1,000 grams, are considered high-risk.

Legal Recourse in 2026: Multidistrict Litigation and Settlement Updates

The legal response to the Elmiron-maculopathy link has been massive. By 2026, the multidistrict litigation (MDL) in the District of New Jersey—presided over by Judge Brian R. Martinotti—has consolidated over 2,500 cases. Bellwether trials have resulted in mixed verdicts, but the overall trend has pushed Janssen toward settlement negotiations. Key developments include:

• Early bellwether outcomes: The first trial in 2022 resulted in a defense verdict, but subsequent trials in 2023 and 2024 yielded plaintiff verdicts of $7.5 million and $11.2 million, respectively.
• Settlement framework: As of early 2026, Janssen has reportedly set aside $1.2 billion for a potential global settlement, with individual payouts ranging from $50,000 to over $500,000 depending on severity of retinal damage and age at diagnosis.
• Statute of limitations: This varies by state, but many courts have applied the "discovery rule," meaning the clock starts when the patient knew—or should have known—that their eye condition was linked to Elmiron, not when they first took the drug.

For patients diagnosed with pigmentary maculopathy after long-term Elmiron use, the path to compensation remains open, but time is of the essence. We recommend consulting with a qualified attorney who specializes in pharmaceutical mass torts, as the settlement window may close once a global agreement is finalized.

Moving forward, the medical community has largely adopted a "screen early, screen often" approach. The American Urological Association now recommends that all patients starting Elmiron receive a baseline retinal exam, with annual follow-ups thereafter. For those already on the drug, immediate cessation under a urologist's guidance—balanced against the severity of interstitial cystitis symptoms—is the standard recommendation. The question is no longer "if" Elmiron causes pigmentary maculopathy, but how best to mitigate the damage already done.